Baidu
map

Allergy Asthma Clin Immunol:中国北方一个乡村地区过敏性和非过敏性鼻炎流行度分析

2018-12-09 AlexYang MedSci原创

大多数流行病学研究报道过敏性鼻炎(AR)和非过敏性鼻炎(NAR)时只评估了自我报道的流行度,并没有进行客观的测量确定。更多的是,关于中国人口的NAR流行度报道非常少见。因此,最近有研究人员探索了中国人口中AR和NAR的流行度和风险因子,且主要基于临床表现和过敏状态。研究人员进行的是一个基于群体的代表性调查,包括了中国北京的1084名当地居民。研究发现,自我报道的AR流行度为46.8%。基于SPT结

大多数流行病学研究报道过敏性鼻炎(AR)和非过敏性鼻炎(NAR)时只评估了自我报道的流行度,并没有进行客观的测量确定。更多的是,关于中国人口的NAR流行度报道非常少见。因此,最近有研究人员探索了中国人口中AR和NAR的流行度和风险因子,且主要基于临床表现和过敏状态。

研究人员进行的是一个基于群体的代表性调查,包括了中国北京的1084名当地居民。研究发现,自我报道的AR流行度为46.8%。基于SPT结果,确定的AR和NAR标准流行度分别为16.78%和24.60%。鼻痒、打喷嚏、鼻漏和充血严重度得分在AR患者中均鼻NAR患者显著更高(P<0.05)。其中在AR自我报道群组中,3种最常见的过敏原为德国小蠊 (16.6%), 粉尘螨(14.6%)和屋尘螨(13.9%)。AR的家族历史和过敏性皮肤炎与AR显著相关(调整后OR:分别为3.53和2.45)。相似的是,并发症、CRS和过敏性皮肤炎为AR和NAR的显著风险因子。

最后,研究人员指出,标准调查问卷和特异性过敏原测试的组合能够为AR和NAR流行度和相关风险因素的评估提供更加准确的结果。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
    2018-12-19 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
    2018-12-11 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047050, encodeId=a293204e0507f, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Mar 19 04:05:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977136, encodeId=3e2919e71360c, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Dec 19 10:05:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711755, encodeId=a8c01e1175569, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Sep 27 10:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651441, encodeId=6f53165144184, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Wed May 01 09:05:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955711, encodeId=6f1e1955e11b1, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jun 06 21:05:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329183, encodeId=cee313291835c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Dec 11 13:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355017, encodeId=dba535501e20, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4ee1660018, createdName=1dde8844m30(暂无匿称), createdTime=Mon Dec 10 14:58:24 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
    2018-12-10 1dde8844m30(暂无匿称)

    学习了

    0

相关资讯

Chin Med J (Engl):舌下免疫治疗药片能够减轻成年人过敏性鼻炎症状

舌下免疫治疗(SLIT)在屋尘螨诱导的过敏性鼻炎中具有很好的治疗效果。然而,成年人过敏性鼻炎中,SLIT药片对其的治疗效果还未见报道。最近,有研究人员通过元分析阐释了SLIT对过敏性鼻炎的差异化治疗效果。研究总共包括了7个相关的研究,总共鉴定了2723名患者。所有的研究均为随机对照研究(RCT),且上述7个研究均在成年人中进行。在这7篇文献中,有5个研究对患者进行了SLIT药片治疗,并且符合鼻炎总

J Laryngol Otol:永久性和间歇性过敏性鼻炎患者中,鼻涂片嗜酸性粒细胞分析

嗜酸性粒细胞是过敏性鼻炎致病机制的首要响应细胞。在非过敏性的鼻炎、过敏性鼻炎、嗜酸性粒细胞过多、阿司匹林过敏和鼻息肉中的细胞数据患者中,细胞的数目均增多。脱落鼻细胞学可以用来对过敏性鼻炎进行不同的诊断。最近,有研究人员评估了具有轻度、永久和间歇性过敏性鼻炎患者的鼻涂片中评估嗜酸性粒细胞。研究包括了60名患有过敏性鼻炎的患者和20名健康志愿者。患者分成间歇性和永久过敏性鼻炎2个小组,并且比较了鼻涂片

Int Arch Allergy Immunol:Notch信号途径能够促进过敏性鼻炎的发展

Notch信号途径在调控人类免疫功能中具有重要的作用,但是过敏性鼻炎(AR)与Ntoch信号途径之间的关系仍旧不清楚。最近,有研究人员调查了Notch信号途径在AR致病和Foxp-3Treg 细胞调控中的作用。研究包括了100名AR患者和50名健康对照。研究发现,与对照组相比,Notch1和Jagged1在AR患者中的表达显著提高(p<0.05)。Notch1和Jagged1在患有重度AR患

Int Arch Allergy Immunol:在过敏性鼻炎中,MiR-202-5p能够促进M2极化

最近,有研究人员调查了MiR-202-5p对过敏性鼻炎中巨噬细胞的影响。研究包括了30名过敏性鼻炎的患者和10名健康的对照。研究人员利用鼻腔灌洗来收集鼻组织和来源于粘液的巨噬细胞,并利用流式细胞仪检测和分选了2型巨噬细胞,并且还利用qRT-PCR和蛋白免疫印迹来确定MiR-202-5p和MATN2的表达情况。研究人员还利用荧光素酶和生物素RNA-pulldown试验测试了miR-202-5p与MA

Allergol Immunopathol (Madr):过敏性鼻炎中,B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析

过敏性鼻炎(AR)是一种经典的Th2调节的疾病,能够引起重要的白介素4、5和13的病理性变化。OX40共刺激分子和它的配体互作参与了Th1/Th2细胞平衡调控的免疫响应。考虑到OX40配体(OX40L)与AR之间相关信息的缺乏,最近,有研究人员调查了OX40配体在B淋巴细胞中的表达。研究包括了20名AR患者和20名健康参与者。研究人员利用电化学发光免疫检测(ECL)技术对总血清lgE水平进行测量,

Eur Arch Otorhinolaryngol: 过敏性鼻炎对鼻粘膜重建的不同影响研究

过敏性鼻炎(AR)已经报道与慢性鼻窦炎(CRS)相关。最近,有研究人员调查了AR对CRS鼻粘膜重建的影响。研究人员将募集的患者分成不同的小组:具有鼻息肉(NP)和过敏性鼻炎(AR)的CRS患者(CRSwNPwAR,n=20)、具有NP,不具有AR的CRS患者(CRSwNPsAR; n?=?20)、不具有NP,具有AR的CRS患者(CRSsNPwAR; n?=?20)、不具有NP和AR的CRS患者(

Baidu
map
Baidu
map
Baidu
map